About Cue Biopharma
Cue Biopharma is a company based in Cambridge (United States) founded in 2015. It operates as a HealthTech. Cue Biopharma has raised $10 million across 2 funding rounds from investors including MDB Capital Holdings. The company has 41 employees as of December 31, 2024. Cue Biopharma offers products and services including Engineered Biologics. Cue Biopharma operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Cambridge, United States
- Employees 41 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cue Biopharma
-
Annual Revenue
$9.29 M (USD)69.16as on Dec 31, 2024
-
Net Profit
-$40.67 M (USD)19.83as on Dec 31, 2024
-
EBITDA
-$39.24 M (USD)19.18as on Dec 31, 2024
-
Total Equity Funding
$10 M (USD)
in 2 rounds
-
Latest Funding Round
$30 M (USD), Post-IPO
Nov 21, 2022
- Investors
-
Employee Count
41
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Cue Biopharma
Cue Biopharma is a publicly listed company on the NASDAQ with ticker symbol CUE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Cue Biopharma
Cue Biopharma offers a comprehensive portfolio of products and services, including Engineered Biologics.
Engineered biologics are designed for immune system activation.
People of Cue Biopharma
Unlock access to complete
Unlock access to complete
Funding Insights of Cue Biopharma
Cue Biopharma has successfully raised a total of $10M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cue Biopharma
Cue Biopharma has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include MDB Capital Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage tech startups are funded by MDB Capital Holdings.
|
Locked | Locked | Locked |
Investor details for Cue Biopharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cue Biopharma
Investment portfolio details for Cue Biopharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cue Biopharma
Detailed financials for Cue Biopharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cue Biopharma Comparisons
Peer comparison for Cue Biopharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cue Biopharma
Cue Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Cue Biopharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cue Biopharma
Complete news archive for Cue Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cue Biopharma
Cue Biopharma was founded in 2015.
Cue Biopharma is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Cue Biopharma is a funded company, having raised a total of $10M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Cue Biopharma is 41.
Annual revenue of Cue Biopharma is $9.29M as on Dec 31, 2024.
Cue Biopharma is engaged in the development of engineered biologics aimed at mobilizing the patients immune system to treat serious diseases. The companys solutions are designed to selectively expand and activate specific immune cells while restoring immune balance. Their work primarily targets autoimmune and inflammatory diseases through innovative approaches in the biotechnology sector, with partnerships such as with Boehringer Ingelheim to advance next-generation treatments.
Cue Biopharma's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Cue Biopharma offers Engineered Biologics.
Yes, Cue Biopharma is publicly traded on NASDAQ under the ticker symbol CUE.
Cue Biopharma has 1 investor. Key investors include MDB Capital Holdings.
The ticker symbol of Cue Biopharma is CUE on NASDAQ.